The use of zoledronic acid in Japanese men with stage D2 prostate cancer

  • Authors:
    • Kogenta Nakamura
    • Yoshiaki Yamada
    • Charles J. Rosser
    • Maki Arakawa
    • Kenji Zennmai
    • Yoshiharu Kato
    • Masahito Watanabe
    • Remi Katsuda
    • Motoi Tobiume
    • Katsuya Naruse
    • Shigeyuki Aoki
    • Tomohiro Taki
    • Hiroko Saito
    • Takaaki Hasegawa
    • Nobuaki Honda
  • View Affiliations

  • Published online on: January 1, 2010     https://doi.org/10.3892/ol_00000002
  • Pages: 13-16
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Zoledronic acid (ZOL) is a new generation bisphosphonate with improved efficacy benefits over pamidronate in preclinical testing. In addition, ZOL is superior to pamidronate in the treatment of hypercalcemia of malignancy. ZOL is also the first bisphosphonate to demonstrate efficacy in patients with bone metastases from solid tumors other than breast cancer, such as prostate cancer. In this study, we investigated ZOL treatment in 17 Japanese men with advanced prostate cancer, treated at the Aichi Medical University Hospital between August 2006 and November 2007. The 17 patients had biopsy-confirmed prostate cancer and were found to harbor bone metastasis upon bone scintigraphy. ZOL was administered intravenously at a dose of 4 mg over 15 min every 4 weeks. ZOL was well tolerated with mild renal dysfunction in 2 patients (11.8%), while 1 patient (5.8%) developed skin rash. No significant side effects were observed. Subjective improvement in bone pain was reported in 14 patients (32.4%). ZOL, therefore, is a safe and effective drug that remains an important component of the urologist's armamentarium against advanced prostate cancer.
View Figures
View References

Related Articles

Journal Cover

January-February 2010
Volume 1 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nakamura K, Yamada Y, Rosser CJ, Arakawa M, Zennmai K, Kato Y, Watanabe M, Katsuda R, Tobiume M, Naruse K, Naruse K, et al: The use of zoledronic acid in Japanese men with stage D2 prostate cancer . Oncol Lett 1: 13-16, 2010
APA
Nakamura, K., Yamada, Y., Rosser, C.J., Arakawa, M., Zennmai, K., Kato, Y. ... Honda, N. (2010). The use of zoledronic acid in Japanese men with stage D2 prostate cancer . Oncology Letters, 1, 13-16. https://doi.org/10.3892/ol_00000002
MLA
Nakamura, K., Yamada, Y., Rosser, C. J., Arakawa, M., Zennmai, K., Kato, Y., Watanabe, M., Katsuda, R., Tobiume, M., Naruse, K., Aoki, S., Taki, T., Saito, H., Hasegawa, T., Honda, N."The use of zoledronic acid in Japanese men with stage D2 prostate cancer ". Oncology Letters 1.1 (2010): 13-16.
Chicago
Nakamura, K., Yamada, Y., Rosser, C. J., Arakawa, M., Zennmai, K., Kato, Y., Watanabe, M., Katsuda, R., Tobiume, M., Naruse, K., Aoki, S., Taki, T., Saito, H., Hasegawa, T., Honda, N."The use of zoledronic acid in Japanese men with stage D2 prostate cancer ". Oncology Letters 1, no. 1 (2010): 13-16. https://doi.org/10.3892/ol_00000002